DMPK Insights #9: 60 and Beyond: Navigating the Frontiers of PBPK and QSP

In this podcast, listeners will join us in celebrating the remarkable career of Professor Amin Rostami, a trailblazer in the realms of PBPK and QSP. Following his 60th birthday, Professor Rostami will provide insights into his journey, the dynamic evolution of PBPK and QSP, and the exciting horizons ahead. Tune in for a deep dive into the intersections of academia and industry, technological advancements, and the invaluable lessons garnered throughout a pioneering career.

The episode explores the following:

• The key milestones and highlights of Professor Amin's career in PBPK and QSP
• The factors that initially captivated his interest in PBPK, and how the field evolved over the decades of his career
• The role of translational and systems pharmacology in shaping the future of drug development
• Balancing between academic and industry roles
• Advice to young scientists and researchers entering the field of PBPK

Speaker:

Amin Rostami-Hodjegan, PhD, FCP, FAAPS, FJSSX, FBPS – Professor of Systems Pharmacology & Director of Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK. SVP of R&D, Chief Scientific Officer (CSO), Certara, Princeton, USA
The work of Professor Rostami covers wide areas of drug development over the last 30 years, ranging from pharmaceutics (e.g. bioavailability and bioequivalence) to clinical pharmacology (e.g. mixture pharmacology of drug/metabolites), translational and systems pharmacology (e.g. quantitative proteomics of enzymes and transporter for in vitro to in vivo (IVIVE) scaling). As the Director of Centre for Applied Pharmacokinetic Research (CAPKR) at the University of Manchester, Amin collaborates with many pharmaceutical companies with a view to transfer latest scientific applications into modern drug development.  Amin was co-founder of two spin-off companies from the University of Sheffield (Simcyp Limited [now part of Certara Inc]) and Diurnal Limited [now part of Neurocrine Bioscience]). As a leader in the field of Physiologically-based Pharmacokinetics (PBPK) and Quantitative Systems Pharmacology (QSP), he is internationally recognized for his expertise in IVIVE to predict the behavior of drugs in human body and understanding the associated inter-individual variabilities. He was one of the founding editors of Pharmacometrics and System Pharmacology and serves on the Editorial Boards of several other journals. As the Senior Vice President of Research & Development (SVP) and Chief Scientific Officer at Certara, he facilitates the incorporation and integration of the latest advances in translational modelling to bio-simulation platforms offered by Certara to its clients, with the aim of accelerating the development and regulatory approval of safer drug products and bringing them to the patients. 

Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!